In cell viability at the indicated doses of Ad-EV vs. Ad-IGFBP3.DiscussionIn this study, we examined the potential role of IGFBP3 as a mediator of the therapeutic effects of imatinib mesylate in GISTs. Our previous studies showed that IGFBP3 is upregulated after imatinib treatment in a responsive GIST cell line (GIST882), and we provide evidence that IGFBP3 does indeed partially mediate GIST882 ce